CAMPATH-1H (where CAMPATH is a trade mark of Wellcome group companies), a humanized IgG antibody used in the therapy of lymphoma, leukaemia and rheumatoid arthritis, has been expressed in Chinese hamster ovary, YO myeloma and NSO myeloma cell lines. These engineered cell lines were grown under different culture conditions, and the antibody isolated and purified. N-Linked oligosaccharides, on the CH 2 heavy chain region of the antibody, were isolated and analysed by hydrazlnolysis, high-performance anionexchange chromatography with pulsed amperometric detection, laser-desorption mass spectrometry and sequential exoglycosidase treatment Both the glycosylation pattern and the biological activity of CAMPATH-1H, as measured by antibody-dependent cell-mediated cytotoxicity, were markedly affected by the cell line used to express the antibody. It is concluded that glycosylation of the antibody may be important in the clinical outcome of therapy.
Introduction
Glycosylation of therapeutic antibodies can have a critical effect on biological activity and pharmacokinetics (Nose and Wigzell, 1983; Parekh et al, 1985; Wright et al, 1991) . The removal of the N-linked oligosaccharide from the CH 2 heavy chain region of the antibody abrogates target cell killing by complement-mediated lysis (CML) and antibody-dependent cell-mediated cytotoxicity (ADCC) (Nose and Wigzell, 1983; Tao and Morrison, 1989) . Circulatory lifetime, immunogenicity and antigenicity of the antibody may also be affected by glycosylation of the molecule (Rademacheref a/., 1988). There are several factors that can influence glycosylation. The species, tissue and cell type have all been shown to be important in the way that glycosylation occurs (Rademacher et al, 1988) . In addition, the extracellular environment, through altered culture conditions such as serum concentration, may have a direct effect on glycosylation (Goochee and Monica, 1990; Maiorella et al., 1993) .
CAMPATH-1H (where CAMPATH is a trade mark of Wellcome group companies), a humanized IgGl antibody (Riechmann et al., 1988) , is directed against the CD52 antigen (Hale et al., 1990; Treumann et al., 1995) present on the cell surface of the majority of normal and malignant lymphocytes. This antibody has been expressed in several mammalian cell lines, including YO rat myeloma, NSO mouse myeloma and Chinese hamster ovary (CHO), grown using different culture conditions, and extensively tested in clinical trials of lymphoproliferative disorders (Hale et al., 1988) and rheumatoid arthritis (Isaacs et al., 1992) , with some major successes.
This study was initiated in order to determine whether differences in glycosylation in CAMPATH-1H were apparent between the different cell lines expressing the antibody, and whether there were corresponding differences in in vitro biological activity, the natural consequence being that glycosylation of the antibody may be important in the clinical outcome of therapy.
Results

Purification and chemical characterization of CAMPATH-1H
CAMPATH-1H was purified from culture supernatants by protein A-Sepharose chromatography. SDS-PAGE (data not shown) showed a single band at 150 kDa (non-reducing gel), and bands at 50 and 25 kDa (reducing gel) for heavy and light chains, respectively. No evidence for free heavy or light chain was observed. Size-exclusion HPLC indicated that the material was present as the monomer with <1% aggregate.
Preparation and analysis of oligosaccharide standards
A series of oligosaccharide standards was obtained commercially, and further standards were derived from these by treatment with exoglycosidases, using pVgalactosidase, a-fucosidase and/or P-N-acetylhexosaminidase. Table I shows the relative retention times of these oligosaccharide standards, analysed by high-performance anion-exchange chromatography (HPAEC), together with the corresponding [M + Na + ] molecular ions observed by laser-desorption mass spectrometry (LD-MS). All structures were as expected and fully confirmed by LD-MS. It is clear that removal of galactose (Gal) and/or N-acetylglucosamine (GlcNAc) from the outer arm of the oligosaccharide reduces, whereas removal of the core fucose (Fuc) residue increases, the relative retention time on HPAEC.
M.RXlfely et al. Oligosaccharides were separated by HPAEC (Figure 1 ) and showed significant differences in their profiles.
Oligosaccharides from CHO-derived CAMPATH-1H, whether grown in the absence (Figure 1 A) or presence ( Figure  IB ) of serum, gave the simplest profile. Comparison of the relative retention times of the three main peaks (I-III; Table II) with those of standards suggested the presence of a major fucosylated series (Figure 2 ; Family 1) whose members differed in terminal galactosylation. LD-MS of the unfractionated oligosaccharides ( Figure 3A ) confirmed the presence of this series, as well as a minor non-fucosylated series ( Figure 2 , Family 2). Each of the main peaks (I-III) was separated by chromatography on HPAEC and further analysed by LD-MS. LD-MS of Peak I ( Figure 3B ) indicated a [M + Na + ] molecular ion at 1487, suggesting the non-galactosylated structure, 004301; Peak II (Figure3C) had a [M + Na + ] molecular ion at 1645, indicating the monogalactosylated structure, 014301; lastly, Peak HI ( Figure 3D ) was a mixture of two major [M + Na + ] molecular ions at 1501 and 1809, indicative of the monogalactosylated, non-fucosylated structure, 014300, and the digalactosylated structure, 024301, respectively. Each of the fractionated oligosaccharides (Peaks I-III), as well as the unfractionated oligosaccharides, was treated with exoglycosidases and analysed by HPAEC and LD-MS. The strategy of exoglycosidase digestion is shown in Scheme 1 and the results, summarized in Table II , are fully consistent.
Oligosaccharides from YO-derived CAMPATH-1H gave a far more complicated profile ( Figure 1C ), although the major peaks CI-III) that dominated the CHO oligosaccharide profile were present. In addition, however, the presence of a fucosylated and non-fucosylated series containing a bisecting GlcNAc (Figure 2 ; Family 3 and Family 4, respectively) was indicated, based on the relative retention times of standard oligosaccharides. LD-MS of the unfractionated oligosaccharides was fully consistent with this interpretation (Table III) . Confirmation of the assigned structures was obtained by exoglycosidase (024301) 2b (014300) la (004301) 2a (004300) 2a (004300) 2b (014300) 2c (024300) 2a (004300) la (004301) 002301 002300 lb (014301) la (004301) 013301 003301 013300 lc (024301) 2b (014300) la (004301) 2a (004300) 2c (024300) 2b (014300) (±Gal)-GkNAc-Maii Fnc
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Man-GkNAt-GlcNAc
Glycosylatlon and biological activity of CAMPATH-1H Figure 1A and B). b Oligosaccharides were incubated with exoglycosidases prior to analysis. G = P-galactosidase; F = a-fucosidase; H = jj-N-acetylhexosaminidase; + indicates treatment with a mixture of exoglycosidases. 'Retention time relative to NeuNAc (see Table I ). d Molecular weight of the [M + Na + ] ion (see Table I ). 'Deduced structure (see Table I and Figure 2 for nomenclature). Two peaks observed by HPAEC, consistent with isomeric structures.
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Family 4 treatment of the unfractionated oligosaccharides with a-fucosidase ( Figure 4A ) or P-galactosidase ( Figure 4B ), or a combination of both a-fucosidase and P-galactosidase ( Figure  4C ), followed by chromatography on HPAEC and LD-MS. Treatment with a-fucosidase revealed the presence of both non-fucosylated series ( Figure 2 ; Family 2 and Family 4), whereas treatment with p-galactosidase showed the presence of the non-galactosylated oligosaccharide from each of Families 1-4. Treatment with both exoglycosidases simplified the HPAEC trace further ( Figure 4C ) to the non-galactosylated oligosaccharide from each of Family 2 and 4. LD-MS of each of the exoglycosidase-treated oligosaccharide mixtures confirmed the proposed assignments. The strategy of exoglycosidase digests is shown in Scheme 2, and the results are summarized in Table III . The profile of oligosaccharides from NS0 antibody ( Figure  ID ) was similar to that from CHO material. The major peaks (I-III) were again present, and their structures were deduced by LD-MS, suggesting that the major fucosylated series, Family 1, is a major contributor and the non-fucosylated series, Family 2 (Figure 2 ), is a minor contributor to the HPAEC profile. These structures were confirmed by exoglycosidase treatment, as described for Y0 oligosaccharides, followed by HPAEC and LD-MS. However, two minor peaks ( Figure ID ; Peak A and B) (±Gal)-GlcNAc-Man
4.
GlcNAc-Man-GlcNAc-GlcNAc with short retention times were observed, that were not found in the CHO or Y0 oligosaccharide HPAEC profiles. Although these structures were not analysed in detail, they appear to be the result of underglycosylation, as outlined below.
Peak II from CHO oligosaccharides was determined to be 014301. Exoglycosidase treatment of this fraction (see Scheme 1) with P-ZV-acetylhexosaminidase (to give 013301), followed by P-galactosidase (to give 003301) or a-fucosidase (to give 013300), produced a series of underglycosylated oligosaccharides whose structures were fully consistent with LD-MS data. They could all be separated into two isomers by HPAEC, with overlapping relative retention times in the range 0.38-0.58 (Table I ). The two minor peaks from NS0 M.RXifelyrta/. "Peaks isolated by fractionation on HPAEC (see Figure 1A and Table II 
Biological activity ofCAMPATH-lH
The concentration of CAMPATH-1H was measured by adsorption at OD 280 nm and by human IgG enzyme-linked immunosorbent assay (ELISA). The ability to bind to CD52 antigen by ELISA and by fluorescent activated cell scan (FACS) staining of antigen-bearing cells was similar for all antibody preparations. Surface plasmon resonance (SPR) analysis indicated no differences in the affinities (range 1.06-1.57 x lO 8 /!^) of the three CAMPATH-1H antibodies (Y0, NS0 and CHO) for the antigen over a range of dilutions. It can be concluded that differences in glycosylation of the various antibody preparations are not reflected in differences in the ability to bind to the CD52 antigen or in the affinity for such an interaction.
The ADCC activity of CAMPATH-1H antibodies from different cell cultures (CHO, Y0 and NS0) was measured using effector cells from a range of donors. The results shown ( Figure 5 ) are typical of several assays, using isolated donors on each occasion, and indicate that, at the lower doses utilized in the assay, Y0 antibody was consistently more active. These results are exemplified by the concentration required to achieve 50% specific lysis (i.e. 0.0001 ^g/ml for the Y0 antibody, and 0.001 and 0.001-0.01 |ig/ml for the NS0 and CHO antibodies, respectively). As expected, removal of N-linked oligosaccharides from CAMPATH-1H abrogated activity (data not shown).
In contrast, no differences between the antibodies in the (004311) lc (024301) 2b (014300) 3b (014311) 4a (004310) 4b (014310) la (004301) 2a (004300) 3a (004311) 4a (004310) 2a (004300) 2b (014300) 4a (004310) 2c (024300) 4b (014310) 2a (004300) 4a (004310) •Released from CAMPATH-1H by hydrazinolysis and fractionated on HPAEC (see Figure 1C) . Retention time relative to NeuNAc (see Table I ). Table I ). 'Deduced structure (see Table I and Figure 2 for nomenclature).
monocyte killing assay were found, although good activity was observed in all cases (data not shown).
Discussion
It is known that both the culture conditions and the cell line can affect the glycosylation pattern of an antibody. It is equally clear that glycosylation plays a role in the biological activity of the antibody. This study was initiated to determine whether expression of the clinically important, humanized monoclonal IgGl antibody, CAMPATH-1H, from different cell lines had an effect on glycosylation and, if so, whether in vitro biological activity was also altered.
The results from this study demonstrate that major differences in antibody glycosylation occur between cell lines, and minor differences occur for a given cell line grown under different culture conditions. Glycosylation patterns differ markedly between the antibodies expressed in CHO (Figure 1 A) , Y0 ( Figure 1C ) and NS0 ( Figure ID) cells. Y0 CAMPATH-1H is remarkable in being the only antibody with a bisecting GlcNAc on the core oligosaccharide (see Figure 2 ; Family 3 and 4), and there is evidence to suggest that the NS0 antibody has a significant degree of underglycosylation ( Figure ID ; Peaks A/B). In contrast, the different culture conditions used in this study result in less significant effects on CHO antibody glycosylation ( Figure 1A and B) , although quantitative differences are observed, suggesting that a higher proportion of oligosaccharide chains have terminal galactose residues when grown in serumcontaining medium (FigurelB; Peak III > Peak I) rather than protein-free medium (FigurelA; Peak I > Peak III).
CAMPATH-1H binds to an antigen (CD52), abundantly expressed on the surface of both normal and malignant (1502) 024300 (1664) 004310 (1542) 014310 (1704) 004301 (1484) 004300 (1340) 004311 (1686) 004310 ( Antibody concentration (ng/ml) lymphocytes, and is remarkably effective in both CML and ADCC in vitro. The antibody has been in major clinical trials for several years, and has proved to be very effective in lymphocyte depletion. The mechanism of lymphocyte depletion does not appear to be via CML, since CAMPATH-1M, a rat IgM, has excellent CML activity in vitro but is ineffective in vivo. In contrast, there is a good correlation between ADCC activity in vitro and lymphocyte depletion in patients. In this study, the biological activity of CAMPATH-IH was measured by both ADCC and monocyte killing. The ADCC assay measures the capacity of CD16 + , CD56 + killer cells (effector cells) to lyse antibody-coated target cells. The specific lytic mechanism is via the CD 16 receptor on the effector cell, which binds to the Fc CH 2 region of IgG when bound to the target cell, and can be affected by the glycosylation pattern of the antibody. The monocyte killing assay is performed over a 5 day time period and utilizes cells of the CD14 + lineage. The mechanism of action is also mediated via antibody interactions, but is monitored by the growth inhibition of the target cells rather than by killing. The IgG Fc receptors found displayed on the monocytes vary with time in culture, and a combination of CD 16, CD32 and CD64 is thought to be involved.
Although all antibodies had similar activity in the monocyte killing assay, YO CAMPATH-IH had enhanced activity over both NSO and CHO antibodies in the ADCC assay. Moreover, the deglycosylated antibody had no ADCC activity, demonstrating the requirement for an N-linked oligosaccharide on the CH 2 region of the heavy chain. This result suggests a relationship between the glycosylation pattern and biological activity, and that oligosaccharide structures containing a bisecting GlcNAc may play an important role. The implication for clinical efficacy is obvious: should the mechanism of lymphocyte depletion in vivo be via ADCC rather than monocyte killing activity, then YO CAMPATH-IH would have a significant benefit over CHO or NSO antibody. It is interesting that, in this study, antibody glycosylation has a markedly different effect on the ADCC and monocyte killing activities, even though the mechanisms of action are both mediated via Fc receptor binding to antibody. It would not be safe to extrapolate these results to other antibodies.
One means of gaining a better understanding of the role of antibody glycosylation in biological systems would be to remove monosaccharide residues from the oligosaccharide chain on an intact antibody molecule in a stepwise fashion. Preliminary experiments in our laboratory demonstrated the feasibility of this approach with CAMPATH-IH (M.R.Lifely, unpublished observations), in which successive treatments with the exoglycosidases, N-acetylneuraminidase, (3-galactosidase and N-acetyl-P-hexosaminidase, removed the appropriate residues, albeit with increased difficulty, without affecting binding activity.
Materials and methods
Source of CAMPATH-IH
The CHO 3D11 cell line expressing CAMPATH-1H using dihydrofolate reductase as a selectable marker (Page and Sydenham, 1991) was grown in either a hollow fibre fermenter (Acusyst-Jr) culture using Iscove's medium lacking HEPES supplemented with non-essential amino acids, 1 uM methotrexate and 5% fetal bovine serum (FBS), or using Wellcome culture medium 5 (WCM5) serum-free medium with 1 ujvl methotrexate in a stirred 8000 I bioreactor. WCM5 contains human recombinant insulin, but is otherwise protein free.
YO antibody was prepared using transfectant TF57 (Riechmann eial., 1988) . The cells were grown in roller bottles using Iscove's medium supplemented with 2% FBS and hypoxanthine/aminopterin/thyrnidine.
For re-expression in NSO cells, the heavy and light chain CAMPATH-IH cDNA was recloned into glutamine synthetase selection-based vectors (Bebbington et al., 1992) obtained from Celltech, Slough, UK, transfected by electroporation, then amplified with 5 uM methionine sulphoximine. NSO 9D4, a clonal cell line, selected in serum-containing medium, was transferred to protein-free growth in WNSD medium, which is of defined composition being free of protein and other large-molecular-weight components. After several weeks of protein-free growth, in shake flasks, culture supernatant was harvested.
Antibody purification
The culture supernatant containing CAMPATH-IH from NSO 9D4 cells was clarified by centrifugation and passed through a 0.2 |im filter. The antibody bound to a protein A-Sepharose column was eluted with 0.1 M citrate buffer (pH 3), bound to a S-Sepharose ion-exchange column, then eluted with 20 mM citrate-phosphate buffer containing 200 mM NaCl. A stock solution at 5.54 mg/1 was prepared and stored at 4°C. Clinical Trial Material grade, serum-free CHO 3D 11-derived CAMPATH-IH was obtained as a 10 mg/ml solution in phosphate-buffered saline (PBS) in a sealed glass ampoule, and stored at 4°C. Clarified supematants from CHO 3D11 or Y0 TF57 were purified using a similar protocol to that above. The S-Sepharose eluate was concentrated, desalted, and separated from dimer and higher aggregates using a Superdex 200 sizeexclusion column and stored in PBS.
Release of oligosaccharides by hydrazinolysis
CAMPATH-IH (5 mg) was dialysed against water to remove salts and freeze-dned in a glass ampoule. Hydrazine (0.1 ml) was added and the sealed ampoule heated at 95°C for 5 h. The released oligosaccharides were separated from hydrazine and peptides by adsorption to a cellulose (Whatman, CF-11) column (Bio-Rad; 1 ml) in butanol:ethanol:acetic acid (4:1:0.5 v/v/v; 1.5 ml). After washing the cellulose in butanol:ethanol:water (4:1:1 v/v/v; 3 x 1 ml), oligosaccharides were /V-rcacetylated in situ with acetic anhydride:methanol (2:5 v/v; 1.4 ml) for 30 min at room temperature. The column was washed with butanolxthanol:water (4:1:1 v/v/v; 4 x 1 ml ), then with methanol (1 ml). Oligosaccharides were then eluted from the column with 0.2 M sodium acetate (2 x 1 ml), further treated with acetic anhydride (0.1 ml) for 30 min then with 0.1 M copper acetate (0.1 ml) for 30 min to convert the acetylhydrazone derivatives to trie unreduced oligosaccharides. Cations (Na + and Cu + ) were removed on an ion-exchange stack column of Chelex 100 (H + form; upper; 0.4 ml) and AG-50 (H + form; lower, 1 ml), and oligosaccharides were recovered as the aqueous eluant, before lyophilization.
Desialylation of oligosaccharides
Oligosaccharides were treated with 40 mM trifluoroacetic acid at 80°C for 1 h under helium to remove sialic acid. Trifluoroacetic acid was removed under a stream of nitrogen at 40°C, and sialic acid content was measured by HPAEC using the conditions for separation of oligosaccharides described above.
Exoglycosidase treatment
The following exoglycosidases were obtained from Oxford Glycosystems: G, p"-galactosidase from bovine testes (x-5013); F, o-fucosidase from bovine epididymis (X-5006); H, {J-N-acetylhexosaminidase from jack bean meal (X-5OO3). Oligosaccharides (5-10 |ig) were incubated with enzyme, following the manufacturer's instructions, at 37°C for 48 h in a total volume of 50 u.1. Samples were purified by passage through a column of Dowex AG 50 (H + form; 0.3 ml) layered upon Dowex AG3 (OH~ form; 0.3 ml). The column was eluted with 3 ml water and the eluate lyophilized.
Nomenclature of N-linked oligosaccharides
N-Linked oligosaccharides present on IgG are made from a core of three mannose (Man) and two GlcNAc residues (see, for example, Figure 2 ). Additional GlcNAc, Gal and NeuNAc residues may be present on the two outer arms, and Fuc may be present on the penultimate GlcNAc core residue. Finally, a bisecting GlcNAc may be present, attached to the core Man. The nomenclature to describe the oligosaccharide structures uses a six-numbered digit which (from left to right) describes the number of NeuNAc (0-2), Gal (0-2), core + outer arm GlcNAc (2-4), bisecting GlcNAc (0 or 1) and Fuc (0 or 1) residues.
Analysis of oligosaccharides by HPAEC-PAD
Oligosaccharides released by hydrazinolysis were analysed by HPAEC using a Dionex Bio LC system and a Carbopak PA-1 column, eluted with a linear
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gradient from 24 to 36 mM sodium acetate in 125 mM NaOH over 20 min at a flow rate of 1 ml/min, and detected by pulsed amperometric detection (PAD) using a gold electrode. An internal standard of NeuNAc was included in order to determine relative retention times of oligosaccharide peaks. Standard oligosaccharides, M3N2F (002304), NGA2F (004301), NA2F (024301), NGA2FB (004311), NA2FB (024311) and RP-2501 (a mixture of 024300, 014301, 024301, 004311, 014311, 024311) were purchased from Oxford Glycosystems. Further standards were derived from a-fucosidase treatment of 002301, 004301, 024301, 004311 and 024311, which gave 002300, 004300, 024300, 004310 and 024310, respectively. In addition, a-fucosidase treatment of RP-2501 gave a mixture of 024300, 014300, 024300, 004310, 014310 and 024310.
Preparative isolation ofCHO oligosaccharide Peaks I-III
The oligosaccharide mixture (30 u;l) was injected and oligosaccharides separated by HPAEC. Each peak was collected separately, desalted on AG-50 (H + form) and rotary evaporated to dryness to remove acetic acid. The residue was dissolved in water and a small proportion was reinjected to confirm lack of contamination with other peaks. Each fraction was lyophilized and stored at -20°C.
Structural determination of oligosaccharides by LD-MS
Samples of desialylated oligosaccharides (1-20 pmol) in water (1 u.1) were mixed with the matrix component 2,3-dihydroxy benzoic acid (1 |il of a 10 mg/ml solution in 50% w/v ethanol) and an aliquot (1 |il) allowed to dry on a sample slide. Samples were ionized following irradiation with a pulse of laser light, and were analysed with a LASERMAT time-of-flight mass spectrometer (Finnigan MAT).
IgG EUSA
Culture supematants were clarified by centrifugation at 13 000 r.p.m. in a microfuge. The wells of a 96 well maxisorp ELISA plate (Nunc, Roskilde, Denmark) were coated with sheep anti-human IgG (Seralab, UK, catalogue no. SDL2015) in PBS (2 |ig/ml; 100 |il) and incubated overnight at 4°C. The excess protein binding sites were blocked by incubation with 1% bovine serum albumin (BSA) fraction V in PBS (200 nl/well) at room temperature for 1 h. The wash buffer used between each step was 0.05% Tween 20-PBS. CAMPATH-1H standard samples (2-fold dilutions from 250 ng/ml) or culture supematants in triplicate in 0.2% BSA, 0.05% Tween 20-PBS (PBT) were added (100 (il/well) and the plate incubated at room temperature for 1.5 h. The plate was washed five times and peroxidase-conjugated sheep anti-human IgG (Sigma) was added (diluted 1:2000 in PBT; 100 ul/well). The plates were incubated at room temperature for 40 min, then washed five times. Tetra-methyl benzidine as substrate (Sigma, Poole, UK) was added (100 u.l/well) and incubated at room temperature until a discernible blue colour was apparent. The reaction was stopped with 2 M H 2 SO 4 (100 |il/well) and the colour measured at an adsorbance of 450 nm.
CAMPATH antigen binding EUSA
This was performed as described previously (Xia et al., 1993) .
Antibody-dependent cell-mediated cytotoxicity assay
Peripheral blood mononuclear cells (PBMC) were separated from defibrinated fresh human blood by centrifugation over a lymphoprep (Nycomed) gradient. Wien 133, a human B cell lymphoma cell line (Nacheva et al., 1987) expressing the CD52 antigen on its cell surface membrane, was grown in log phase, labelled with 3l Cr, washed, resuspended at 2 x lOVml, then aliquoted into 96 well 'U'-bottomed tissue culture plates at 50 ul/well. Wien 133 cells were cultured using Iscoves's medium, 10% FBS and 2 mM L-glutamine (Wien growth medium). CAMPATH-1H antibody dilutions (50 (il), in Wien growth medium, were added to triplicate wells in the plate. Nine control wells without antibody were also included in each assay. The plates were incubated at 37°C for 1.5 h in a humid CO 2 incubator prior to the addition of 100 \l\ of PBMC effector cells at a concentration of 2.5 x IO*/ml, in Wien growth medium, to each antibody-containing well. This resulted in a ratio of 25 effector cells for each target cell. The effector cells were also added to one triplicate set of control wells (non-antibody-mediated lysis control), Wien growth medium alone was added to yet another set of control triplicates (spontaneous lysis control) and 100 |il of 1% w/v Triton XIOO were added to the final set of control wells (total release control). The plates were centrifuged for 5 min at 1500 r.p.m. before being replaced at 37°C for 5 h. At the end of the incubation period, 100 u.1 of medium were removed from each well and counted in a Y counter (Wallac Wizard, Model 1470, Turku, Finland) . The level of specific release was calculated as follows 
Monocyte killing assay
Human peripheral blood monocytes were isolated from PBMC by adherence to plastic. This was performed by diluting PBMC in RPMI 1640 medium containing 10% autologous serum (RPMI-S) and incubating for 2 h at 37°C in a 75 cm 2 tissue culture flask. Non-adherent cells were removed by washing twice with RPMI 1640 medium. Monocytes were subsequently cultured for -14 days in RPMI-S and then assayed for CD 14 expression by FACS. The cells were harvested and dispensed into 96 well plates at lOVml and 100 |il/well together with 4 x 10 3 CD52-expressing Wien 133 target cells A range of CAMPATH-1H antibody dilutions, in triplicate, was then added and the plates incubated for 5 days. Target cell proliferation rate was assessed by incorporation of [ 3 H]thymidine. Growth inhibition due to monocyte cytotoxicity was expressed as percentage inhibition in comparison with duplicate cultures in the absence of monocytes.
Fluorescent activated cell scan
To compare antigen binding of the different antibodies, Wien 133 cells were washed and resuspended in PBS containing 5% FBS, 0.1% sodium azide at lOVml, and 100 nl aliquoted into the wells of a 96 well plate. A range of antibody dilutions were subsequently added to the wells and the plate placed at 4°C for 30 min. After washing in the same buffer, the cells were resuspended in 100 u.1 of fluorescein isothiocyanate-labelled anti-human IgG diluted 1 in 100 and again placed at 4°C for 20 min. After extensive washing, the cells were resuspended in PBS containing 1% v/v paraformaldehyde and analysed on a Becton Dickinson FACscan.
Surface plasmon resonance binding
Real-time biospecific interaction analysis using a BIAcore™ (Pharmacia Biosensor AB, Sweden) with SPR was used to determine rate and affinity constants for the various preparations of CAMPATH-1H. This was accomplished by activating the surface of a dextran-coated gold chip with the amine coupling kit (Pharmacia) and coupling the purified CAMPATH antigen, CD52 (Xia et al., 1993) in 10 mM HEPES, 1 M NaCl, pH 7.4 (0.4 nmol CD52 in 80 uJ). CAMPATH-IH, diluted to 3-100 ng/ml in 10 mM HEPES, 150 mM NaCl (pH 7.4), 0.05% BIAcore Surfactant P20 (HBS), was exposed to the coupled antigen for 6 min at a flow rate of 5 ul/min. This was followed by a dissociation phase in which HBS alone was injected. Finally, the antigen surface was regenerated by exposure to 10 mM NaOH for I min and monitoring binding of the antibody to the antigen.
